Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Strategy of Intracoronary Imaging Guided Drug-Coated Balloon Therapy for De Novo Lesions in Large Coronary Vessels (STENTLESS II)

10. november 2026 opdateret af: Erli Zhang, China National Center for Cardiovascular Diseases

Strategies of Intracoronary Imaging Guided Drug-coated Balloons (DCB) Versus Angiography Guided Drug-Coated Balloon Therapy for De Novo Lesions in Large Coronary Vessels Trial (STENTLESS II)

A number of 2570 patients scheduled for percutaneous coronary intervention (PCI) with de novo large coronary vessel lesions (reference vessel diameter ≧2.75 mm) suitable for DCB implantation are openly randomized 1:1 to either intracoronary imaging guidance or angiographic guidance groups. The primary objective is to determine whether the IVUS/OCT-guided DCB strategy reduces the incidence of target vessel failure (TVF) at 12 months compared with the coronary angiography (CAG)-guided strategy.

Studieoversigt

Detaljeret beskrivelse

This study is a prospective, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of IVUS/OCT-guided drug-coated balloon (DCB) strategy compared with a CAG-guided strategy in patients with de novo large coronary vessel lesions (reference vessel diameter ≧2.75 mm). Both groups will follow standardized angiographic safety criteria, with bailout drug-eluting stent (DES) implantation permitted when necessary. In the IVUS/OCT-guided group, lesion assessment, preparation, DCB treatment, and bailout stenting decisions will be optimized according to a predefined IVUS/OCT criterion, whereas the CAG-guided group will undergo treatment primarily based on angiographic assessment.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

2570

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Beijing, Kina, 100037
        • Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

Participants must meet all of the following three criteria:

  1. Age ≥18 years;
  2. De novo lesions of large coronary vessels with the diameter of target lesion reference vessel ≥ 2.75 mm;
  3. One or more trial target vessel (LAD, LCX or RCA) is considered to require intervention and is suitable for treatment with DCB.

Exclusion Criteria:

Participants who meet any of the following conditions are not eligible for inclusion:

  1. Patients with hemodynamically unstable acute coronary syndrome
  2. Previous percutaneous coronary intervention (including stent implantation, plain old balloon angioplasty, and DCB angioplasty) on the target vessel within 12 months
  3. In-stent restenosis requiring revascularization
  4. Complex Coronary Bifurcation Lesions*
  5. Lesions with any of the following anatomical characteristics are presumably not suitable for DCB treatment:

1) Chronic total occlusion* 2) Left main coronary artery lesion and left main bifurcation lesion 3) Venous or arterial graft lesion 4) Moderated-Severe tortuous, or severe angulated vessels 6. cardiogenic shock 7. Concurrent medical condition with a life expectancy of less than 1 year. 8. Known contraindication to medications such as Aspirin, Heparin, antiplatelet drugs, or contrast

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Intracoronary imaging-Guided Drug-coated balloon strategy

DCB diameter and length will be determined based on Intracoronary imaging measurements, with additional lesion preparation performed at the operator's discretion according to the predefined intravascular imaging optimization criteria.

In the intracoronary imaging-guided group, lesion preparation will be guided by intravascular imaging findings, with additional balloon dilatation or specialized devices used as needed. Following lesion preparation and DCB treatment, repeat Intracoronary imaging will be performed to assess lumen gain, residual stenosis, dissection morphology, and elastic recoil. The acceptable minimum lumen area (MLA) is ≥ 4.2 mm², with a target optimization criterion of MLA ≥ 70% of the mean reference lumen area. Patients meeting both the intracoronary imaging criteria and angiographic safety criteria will proceed to DCB treatment. If these criteria are not achieved but angiographic safety criteria are satisfied and the patient remains clinically stable, further optimization may be considered. If angiographic safety criteria remain unmet after observation, bailout drug-eluting stent (DES) implantation will be performed.

Aktiv komparator: CAG-guided Drug-coated balloon strategy

In the CAG-guided group, DCB treatment will be guided by conventional coronary angiography, with DCB diameter and length determined by visual angiographic assessment.

For patients randomized to the CAG-guided group, the selection of lesion preparation devices, DCB sizing, and the need for bailout stenting will be determined by the operators based on coronary angiographic findings and clinical judgment. Patients meeting the predefined angiographic safety criteria after lesion preparation will proceed to DCB treatment. Bailout drug-eluting stent (DES) implantation will be performed if angiographic safety criteria are not met.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Target vessel failure
Tidsramme: 12 months

Incidence of a composite of cardiac death, target-vessel myocardial infarction and clinically indicated target vessel revascularization

12 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Device success
Tidsramme: 0 day (during index PCI)
  • Successful delivery in time and inflation within 30-60 s of the allocated DCB device at the intended target lesion during an attempt with a DCB not previously used (first use)
  • Successful delivery at the target lesion with final in-device residual stenosis ≤ 30% (DCB) or ≤ 20% (DES) by core laboratory QCA (preferred methodology) or visual assessment
  • No rescue procedure by stent
0 day (during index PCI)
Procedure success
Tidsramme: 7 days

Device success Freedom from in-hospital TVF

7 days
Periprocedural complications
Tidsramme: 48 hours

Incidence of a composite of cardiac death, periprocedural myocardial infarction, acute target lesion/vessel thrombosis, and acute target lesion/vessel occlusion

48 hours
Incidence of cardiac death
Tidsramme: 1, 12, 24, 36, and 60 months

Incidence of cardiac death

1, 12, 24, 36, and 60 months
Incidence of target-vessel myocardial infarction
Tidsramme: 1, 12, 24, 36, and 60 months

Incidence of target-vessel myocardial infarction

1, 12, 24, 36, and 60 months
Incidence of clinically indicated target vessel revascularization
Tidsramme: 1, 12, 24, 36, and 60 months

Incidence of clinically indicated target vessel revascularization

1, 12, 24, 36, and 60 months
Patient-oriented composite endpoint (PoCE)
Tidsramme: 1, 12, 24, 36, and 60 months

Incidence of a composite of all-cause mortality, any myocardial infarction, any stroke, and any revascularization

1, 12, 24, 36, and 60 months
all-cause mortality
Tidsramme: 1, 12, 24, 36, and 60 months

all-cause mortality

1, 12, 24, 36, and 60 months
Any myocardial infarction
Tidsramme: 1, 12, 24, 36, and 60 months

Any myocardial infarction

1, 12, 24, 36, and 60 months
Any stroke
Tidsramme: 1, 12, 24, 36, and 60 months

Any stroke

1, 12, 24, 36, and 60 months
Any revascularization
Tidsramme: 1, 12, 24, 36, and 60 months

Any revascularization

1, 12, 24, 36, and 60 months
Incidence of net clinical benefit (a composite of cardiac death, target-vessel myocardial infarction, clinically indicated target vessel revascularization and major bleeding)
Tidsramme: 1,12, 24, 36, and 60 months

Incidence of net clinical benefit (a composite of cardiac death, target-vessel myocardial infarction, clinically indicated target vessel revascularization and major bleeding (Bleeding type 3 or 5 according to the Bleeding ARC))

1,12, 24, 36, and 60 months
Incidence of BARC (Bleeding Academic Research Consortium [BARC] definition, type 2,3 or 5)
Tidsramme: 1, 12, 24, 36, and 60 months

Incidence of BARC (Bleeding Academic Research Consortium [BARC] definition, type 2,3 or 5)

1, 12, 24, 36, and 60 months
Hierarchical composite clinical endpoint of cardiovascular death, TV-MI, and clinically driven TVR
Tidsramme: 1, 12, 24, 36 and 60 months

Hierarchical composite clinical endpoint of cardiovascular death, TV-MI, and clinically driven TVR

1, 12, 24, 36 and 60 months
Hierarchical composite clinical endpoint of any death, any stroke, any MI, BARC defined type 3 bleeding events, any revascularization and BARC type 2 bleeding events
Tidsramme: 1, 12, 24, 36 and 60 months

Hierarchical composite clinical endpoint of any death, any stroke, any MI, BARC defined type 3 bleeding events, any revascularization and BARC type 2 bleeding events

1, 12, 24, 36 and 60 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. december 2026

Primær færdiggørelse (Anslået)

31. december 2028

Studieafslutning (Anslået)

31. december 2031

Datoer for studieregistrering

Først indsendt

10. november 2026

Først indsendt, der opfyldte QC-kriterier

10. november 2026

Først opslået (Faktiske)

16. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Deidentified individual participant data that underlie the results reported in the primary publication will be made available to qualified researchers upon reasonable request and approval of a methodologically sound research proposal, subject to an appropriate data use agreement.

IPD-delingstidsramme

Beginning 36 months after publication of the primary study results and continuing for 5 years.

IPD-delingsadgangskriterier

Deidentified individual participant data underlying the results reported in the primary publication will be available to qualified researchers who submit a methodologically sound research proposal. Requests will be reviewed by the study investigators and, where applicable, relevant institutional or ethics authorities. Proposals that substantially overlap with prespecified ongoing analyses may be deferred until completion of those analyses. Data will be provided for the purposes specified in the approved proposal, subject to an appropriate data use agreement and applicable privacy and data protection requirements.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner